Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma

Overview

Journal Endocrinology

Publisher Oxford University Press

Specialty Endocrinology

Date 2022 Jul 7

PMID 35797592

Authors

Kate M Warde

Yi Jan Lim

Eduardo Ribes Martinez

Felix Beuschlein

Paula OShea

Constanze Hantel

Michael Conall Dennedy

Affiliations

Soon will be listed here.

Abstract

Introduction: Adrenocortical carcinoma (ACC) is a rare aggressive cancer with low overall survival. Adjuvant mitotane improves survival but is limited by poor response rates and resistance. Mitotane's efficacy is attributed to the accumulation of toxic free cholesterol, predominantly through cholesterol storage inhibition. However, targeting this pathway has proven unsuccessful. We hypothesize that mitotane-induced free-cholesterol accumulation is also mediated through enhanced breakdown of lipid droplets.

Methodology: ATCC-H295R (mitotane-sensitive) and MUC-1 (mitotane-resistant) ACC cells were evaluated for lipid content using specific BODIPY dyes. Protein expression was evaluated by immunoblotting and flow cytometry. Cell viability was measured by quantifying propidium iodide-positive cells following mitotane treatment and pharmacological inhibitors of lipolysis.

Results: H295R and MUC-1 cells demonstrated similar neutral lipid droplet numbers at baseline. However, evaluation of lipid machinery demonstrated distinct profiles in each model. Analysis of intracellular lipid droplet content showed H295R cells preferentially store cholesteryl esters, whereas MUC-1 cells store triacylglycerol. Decreased lipid droplets were associated with increased lipolysis in H295R and in MUC-1 at toxic mitotane concentrations. Pharmacological inhibition of lipolysis attenuated mitotane-induced toxicity in both models.

Conclusion: We highlight that lipid droplet breakdown and activation of lipolysis represent a putative additional mechanism for mitotane-induced cytotoxicity in ACC. Further understanding of cholesterol and lipids in ACC offers potential novel therapeutic exploitation, especially in mitotane-resistant disease.

Citing Articles

A Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma.

Flauto F, De Martino M, Vitiello C, Pivonello R, Colao A, Damiano V Cancers (Basel). 2024; 16(23).

PMID: 39682247 PMC: 11640523. DOI: 10.3390/cancers16234061.

Polyamine Pathway Inhibitor DENSPM Suppresses Lipid Metabolism in Pheochromocytoma Cell Line.

Ghayee H, Costa K, Xu Y, Hatch H, Rodriguez M, Straight S Int J Mol Sci. 2024; 25(18).

PMID: 39337514 PMC: 11432427. DOI: 10.3390/ijms251810029.

Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.

Zhang J, Wu L, Su T, Liu H, Jiang L, Jiang Y Front Endocrinol (Lausanne). 2024; 15:1365321.

PMID: 38779454 PMC: 11109426. DOI: 10.3389/fendo.2024.1365321.

Preclinical Models of Adrenocortical Cancer.

Sedlack A, Hatfield S, Kumar S, Arakawa Y, Roper N, Sun N Cancers (Basel). 2023; 15(11).

PMID: 37296836 PMC: 10251941. DOI: 10.3390/cancers15112873.

Prognostic Value of Microscopic Tumor Necrosis in Adrenal Cortical Carcinoma.

Luconi M, Cantini G, van Leeuwaarde R, Roebaar R, Fei L, Propato A Endocr Pathol. 2023; 34(2):224-233.

PMID: 36952130 PMC: 10264263. DOI: 10.1007/s12022-023-09760-6.

References

Endemann G, Stanton L, Madden K, Bryant C, WHITE R, Protter A . CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993; 268(16):11811-6. View

Hoekstra M, Meurs I, Koenders M, Out R, Hildebrand R, Kruijt J . Absence of HDL cholesteryl ester uptake in mice via SR-BI impairs an adequate adrenal glucocorticoid-mediated stress response to fasting. J Lipid Res. 2008; 49(4):738-45. DOI: 10.1194/jlr.M700475-JLR200. View

Smith D, Kroiss M, Kebebew E, Habra M, Chugh R, Schneider B . A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. 2020; 38(5):1421-1429. DOI: 10.1007/s10637-020-00899-1. View

Shawa H, Deniz F, Bazerbashi H, Hernandez M, Vassilopoulou-Sellin R, Jimenez C . Mitotane-induced hyperlipidemia: a retrospective cohort study. Int J Endocrinol. 2013; 2013:624962. PMC: 3848058. DOI: 10.1155/2013/624962. View

Goldstein J, Brown M . Regulation of the mevalonate pathway. Nature. 1990; 343(6257):425-30. DOI: 10.1038/343425a0. View

Hantel C, Shapiro I, Poli G, Chiapponi C, Bidlingmaier M, Reincke M . Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget. 2016; 7(48):79292-79304. PMC: 5346714. DOI: 10.18632/oncotarget.12685. View

Rozeveld C, Johnson K, Zhang L, Razidlo G . KRAS Controls Pancreatic Cancer Cell Lipid Metabolism and Invasive Potential through the Lipase HSL. Cancer Res. 2020; 80(22):4932-4945. PMC: 7669720. DOI: 10.1158/0008-5472.CAN-20-1255. View

Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P . Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2017; 102(4):1358-1365. DOI: 10.1210/jc.2016-2894. View

LaPensee C, Mann J, Rainey W, Crudo V, Hunt 3rd S, Hammer G . ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs. Endocrinology. 2016; 157(5):1775-88. DOI: 10.1210/en.2015-2052. View

10.

Li P, Lu M, Shi J, Gong Z, Hua L, Li Q . Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nat Immunol. 2020; 21(11):1444-1455. PMC: 7584447. DOI: 10.1038/s41590-020-0783-5. View

11.

Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O . Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014; 46(6):607-12. DOI: 10.1038/ng.2953. View

12.

Connelly M, Klein S, Azhar S, Abumrad N, Williams D . Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J Biol Chem. 1998; 274(1):41-7. DOI: 10.1074/jbc.274.1.41. View

13.

Doghman M, Lalli E . Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. Mol Cell Endocrinol. 2013; 381(1-2):66-9. DOI: 10.1016/j.mce.2013.07.023. View

14.

Bilimoria K, Shen W, Elaraj D, Bentrem D, Winchester D, Kebebew E . Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113(11):3130-6. DOI: 10.1002/cncr.23886. View

15.

Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton P . Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007; 356(23):2372-80. DOI: 10.1056/NEJMoa063360. View

16.

Kraemer F . Adrenal cholesterol utilization. Mol Cell Endocrinol. 2007; 265-266:42-5. DOI: 10.1016/j.mce.2006.12.001. View

17.

Paci A, Hescot S, Seck A, Jublanc C, Mercier L, Vezzosi D . Dyslipidemia causes overestimation of plasma mitotane measurements. Endocrinol Diabetes Metab Case Rep. 2016; 2016:150135. PMC: 4901334. DOI: 10.1530/EDM-15-0135. View

18.

Hsieh K, Lee Y, Londos C, Raaka B, Dalen K, Kimmel A . Perilipin family members preferentially sequester to either triacylglycerol-specific or cholesteryl-ester-specific intracellular lipid storage droplets. J Cell Sci. 2012; 125(Pt 17):4067-76. PMC: 3482316. DOI: 10.1242/jcs.104943. View

19.

Nimmakayala R, Leon F, Rachagani S, Rauth S, Nallasamy P, Marimuthu S . Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Oncogene. 2020; 40(1):215-231. PMC: 10041665. DOI: 10.1038/s41388-020-01518-2. View

20.

Yue S, Li J, Lee S, Lee H, Shao T, Song B . Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014; 19(3):393-406. PMC: 3969850. DOI: 10.1016/j.cmet.2014.01.019. View